Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Operating Expenses: 2022-2025

Historic Operating Expenses for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $34.0 million.

  • Taysha Gene Therapies' Operating Expenses rose 22.89% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.4 million, marking a year-over-year increase of 11.01%. This contributed to the annual value of $99.8 million for FY2024, which is 13.54% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Operating Expenses stood at $34.0 million, which was up 18.39% from $28.7 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Operating Expenses ranged from a high of $56.5 million in Q4 2022 and a low of $19.9 million during Q4 2023.
  • In the last 3 years, Taysha Gene Therapies' Operating Expenses had a median value of $23.7 million in 2025 and averaged $24.9 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Operating Expenses slumped by 64.85% in 2023, and later spiked by 31.86% in 2024.
  • Taysha Gene Therapies' Operating Expenses (Quarterly) stood at $56.5 million in 2022, then plummeted by 64.85% to $19.9 million in 2023, then grew by 10.60% to $22.0 million in 2024, then rose by 22.89% to $34.0 million in 2025.
  • Its Operating Expenses stands at $34.0 million for Q3 2025, versus $28.7 million for Q2 2025 and $23.7 million for Q1 2025.